Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A. O’Connor, Josep M. Roncero, Judith Trotman et al.|Journal of Clinical Oncology|2019Cited by 154
First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)Owen A. O’Connor, Andrei R. Shustov, Muhıt Özcan et al.|Blood|2015Cited by 24